Short-course treatment for tuberculosis: past achievements and future directions

doi:10.19982/j.issn.1000-6621.20240219

Abstract

Abstract:

The global decline in tuberculosis (TB) incidence has been disappointingly slow, significantly lagging behind the milestones set by the World Health Organization’s End TB Strategy. Consequently, the development and implementation of effective short-course treatment regimens have become imperative. This review aims to examine the progress of short-course TB treatments over the past few decades and evaluate the efficacy of current therapeutic approaches, providing essential references and support for optimizing future treatment strategies. Through a systematic review of the literature and the latest clinical trial data, we analyzed the efficacy, safety, and application scenarios of various short-course treatment regimens. Furthermore, we summarized the main strategies for current short-course treatments. Despite existing challenges, significant progress in tuberculosis short-course treatment is anticipated in the coming years, driven by the development of novel drugs, dose optimization, and more precise patient evaluation.

Key words: Tuberculosis, Clinical protocols, Therapeutic uses, Consensus reports

CLC Number:

R52
R825.2

Li Yang, Sun Feng, Zhang Wenhong. Short-course treatment for tuberculosis: past achievements and future directions[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 991-997. doi: 10.19982/j.issn.1000-6621.20240219

References 50

[1]	舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读. 结核与肺部疾病杂志, 2024, 5(1):15-19. doi:10.19983/j.issn.2096-8493.2024006.
[2]	Millington KA, White RG, Lipman M, et al. The 2023 UN high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis. Lancet Respir Med, 2024, 12(1): 10-13. doi:10.1016/S2213-2600(23)00409-5.
[3]	李杨, 吴利俊, 王钰琛, 等. 2016—2021年全球结核研究现状及热点:基于VOSviewer的可视化分析. 复旦学报(医学版), 2022, 49(2): 159-167. 10.3969/j.issn.1672-8467.2022.02.001.
[4]	Lee A, Xie YL, Barry CE, et al. Current and future treatments for tuberculosis. BMJ, 2020, 368: m216. doi:10.1136/bmj.m216.
[5]	Bignall J, Rist N. An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis. A trial directed by the Committee on Treatment and the Committee on Bacteriology and Immunology of the International Union against Tuberculosis. Bull Int Union Tuberc, 1964, 34: 79-191.
[6]	McCune RM Jr, McDermott W, Tompsett R.The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. Ⅱ. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med, 1956, 104(5): 763-802. doi:10.1084/jem.104.5.763.
[7]	Grumbach F. Activity of rifampicin on experimental tuberculosis in mice. The development of resistance to rifampicin. Therapeutic effects of combinations of different drugs with rifampicin. Antibiot Chemother, 1970, 16: 392-405. pmid: 5002305
[8]	Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet, 1972, 1(7760): 1079-1085. pmid: 4112569
[9]	Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet, 1974, 2(7875): 237-240.
[10]	Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet, 1975, 1(7899): 119-124.
[11]	Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study. Am Rev Respir Dis, 1978, 118(1): 39-48. doi:10.1164/arrd.1978.118.1.39.
[12]	Aguilar Diaz JM, Abulfathi AA, Te Brake LH, et al. New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians. Respiration, 2023, 102(2): 83-100. doi:10.1159/000528274.
[13]	常蕴青, 顾瑾, 付亮, 等. 耐多药结核病短程治疗研究进展. 中华传染病杂志, 2018, 36(11): 697-700. doi:10.3760/cma.j.issn.1000-6680.2018.11.015.
[14]	Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med, 2021, 384(18): 1705-1718. doi:10.1056/NEJMoa2033400.
[15]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment. Geneva: World Health Organization, 2022.
[16]	Feng Z, Miao Y, Peng Y, et al. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T)(ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial. BMC Infect Dis, 2023, 23(1): 300. doi:10.1186/s12879-023-08264-2.
[17]	Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. N Engl J Med, 2023, 388(10): 873-887. doi:10.1056/NEJMoa2212537.
[18]	Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med, 2019, 380(13): 1201-1213. doi:10.1056/NEJMoa1811867.
[19]	Goodall RL, Meredith SK, Nunn AJ, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet, 2022, 400(10366): 1858-1868. doi:10.1016/S0140-6736(22)02078-5. pmid: 36368336
[20]	Hewison C, Khan U, Bastard M, et al. Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort. Clin Infect Dis, 2022, 75(6): 1006-1013. doi:10.1093/cid/ciac019. pmid: 35028659
[21]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med, 2020, 382(10): 893-902. doi:10.1056/NEJMoa1901814.
[22]	Nyang’wa BT, Berry C, Kazounis E, et al. A 24-week, alloral regimen for rifampin-resistant tuberculosis. N Engl J Med, 2022, 387(25): 2331-2343. doi:10.1056/NEJMoa-2117166.
[23]	Nyang’wa BT, Berry C, Kazounis E, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med, 2024, 12(2): 117-128. doi:10.1016/S2213-2600(23)00389-2.
[24]	World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2022.
[25]	Weng T, Sun F, Li Y, et al. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infect Dis, 2021, 21(1): 183. doi:10.1186/s12879-021-05870-w.
[26]	Mok J, Lee M, Kim DK, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet, 2022, 400(10362): 1522-1530. doi:10.1016/S0140-6736(22)01883-9. pmid: 36522208
[27]	Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study). Am J Respir Crit Care Med, 2022, 205(10): 1214-1227. doi:10.1164/rccm.202107-1779OC.
[28]	Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis, 2023, 76(3): e938-e946. doi:10.1093/cid/ciac528.
[29]	Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011, 365(23): 2155-2166. doi:10.1056/NEJMoa1104875.
[30]	Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med, 2018, 379(5): 440-453. doi:10.1056/NEJMoa1714283.
[31]	Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med, 2019, 380(11): 1001-1011. doi:10.1056/NEJMoa1806808.
[32]	Ruan QL, Huang XT, Yang QL, et al. Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial. Clin Microbiol Infect, 2021, 27(4): 576-582. doi:10.1016/j.cmi.2020.06.008.
[33]	Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018, 52(6):1801470. doi:10.1183/13993003.01470-2018.
[34]	Ismail NA, Omar SV, Moultrie H, et al. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis, 2022, 22(4): 496-506. doi:10.1016/S1473-3099(21)00470-9.
[35]	Azimi T, Khoshnood S, Asadi A, et al. Linezolid resistance in multidrug-resistant Mycobacterium tuberculosis: A systematic review and meta-analysis. Front Pharmacol, 2022,13: 955050. doi:10.3389/fphar.2022.955050.
[36]	Diacon AH. Two Steps Forward, One Step Back. N Engl J Med, 2022, 387(25): 2380-2381. doi:10.1056/NEJMe2214707.
[37]	Ramey ME, Kaya F, Bauman AA, et al. Drug distribution and efficacy of the DprE 1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model. Antimicrob Agents Chemother, 2023, 67(11): e0059723. doi:10.1128/aac.00597-23.
[38]	Holt E. Phase 2 trial of a novel tuberculosis drug launched. Lancet Microbe, 2024, 5(4): e316. doi:10.1016/S2666-5247(23)00401-9.
[39]	Boeree MJ, Lange C, Thwaites G, et al. UNITE4TB: a new consortium for clinical drug and regimen development for TB. Int J Tuberc Lung Dis, 2021, 25(11): 886-889. doi:10.5588/ijtld.21.0515. pmid: 34686229
[40]	Fox GJ, Nguyen CB, Nguyen TA, et al. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. BMJ Open, 2020, 10(1):e033945. doi:10.1136/bmjopen-2019-033945.
[41]	Peloquin CA. Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci, 2001, 953: 157-164. doi:10.1111/j.1749-6632.2001.tb11374.x.
[42]	Velásquez GE, Brooks MB, Coit JM, et al. Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial. Am J Respir Crit Care Med, 2018, 198(5): 657-666. doi:10.1164/rccm.201712-2524OC.
[43]	Onorato L, Gentile V, Russo A, et al. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect, 2021, 27(6): 830-837. doi:10.1016/j.cmi.2021.03.031.
[44]	Jindani A, Atwine D, Grint D, et al. Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis. NEJM Evid, 2023, 2(9): EVIDoa2300054. doi:10.1056/EVIDoa-2300054.
[45]	宋凌云, 张忆琳, 孙峰, 等. 持续提高耐药结核病治疗安全性的挑战与对策. 中华传染病杂志, 2023, 41(12): 797-801. doi:10.3760/cma.j.cn311365-20230729-00020.
[46]	胡艳梅, 罗丹霖, 李杨, 等. 利奈唑胺治疗耐多药肺结核患者的不良反应分析. 中华传染病杂志, 2022, 40(8): 476-482. doi:10.3760/cma.j.cn311365-20210710-00247.
[47]	Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med, 2022, 387(9): 810-823. doi:10.1056/NEJMoa2119430.
[48]	Fregonese F, Apriani L, Barss L, et al. High dose rifampin for 2 months vs standard dose rifampin for 4 months, to treat TB infection: Protocol of a 3-arm randomized trial (2R2). PLoS One, 2023, 18(2): e0278087. doi:10.1371/journal.pone.0278087.
[49]	Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med, 2022, 386(10): 911-922. doi:10.1056/NEJMoa2104535.
[50]	初乃惠, 周文强. 耐药结核病的诊治进展. 中华传染病杂志, 2021, 39(7): 385-391. doi:10.3760/cma.j.cn311365-20210414-00133.